萬里馬(300591.SZ):林大權已減持677萬股
格隆匯3月11日丨萬里馬(300591.SZ)公佈,截至公告披露日,林大權的股份減持計劃減持數量已過半,林大權此次通過集中競價交易、大宗交易方式合計減持677萬股,林大洲此次未減持公司股份。林大權、林大洲決定減持計劃中剩餘待減持部分不再減持,此次減持計劃提前終止。
之前公告披露,公司控股股東、實際控制人林大洲、林大權擬在減持計劃公告之日起15個交易日之後的6個月內(即自2020年3月2日至2020年9月1日)通過集中競價或大宗交易的方式分別減持公司股份不超過256.425萬股和679.575萬股,分別佔公司總股本的和0.82%和2.18%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.